JPRN-UMIN000004641已完成2 期
Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer - Phase II clinical trial of peptide vaccination with chemotherapy in patients with unresectable advanced pancreatic cancer
Department of Gastroenterology Juntendo University School of Medicine0 个研究点目标入组 40 人开始时间: 2010年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.
研究者
相似试验
已完成
1 期
PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer refractory to standard therapeutic modalityJPRN-UMIN000004389Department of Gastroenterological Surgery,Graduate School of Medicine,Osaka University30
已完成
1 期
Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent pancreatic cancer to be refractory to chemotherapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatiopancreatic cancerJPRN-UMIN000002022Department of Gastroenterology, Juntendo University School of Medicine36
已完成
1 期
Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent gastric cancer to be refractory to chemotherapy by using new tumor antigen URLC10 and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatiogastric cancerJPRN-UMIN000002409Department of Gastroenterology, Juntendo University School of Medicine36
已完成
1 期
Phase II study of peptide vaccination for patients with metastatic lung or gastro-intestinal tract cancerslung cancer, pharyngeal cancer, gastric cancer, jejunal cancer, ileal cancer, pancreas cancer, biliary tract cancer, soft tissue sarcomaJPRN-UMIN000002857Tohoku University Hospital14
已完成
1 期
Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinomaAdvanced esophageal cancer refractory to standard therapeutic modalityJPRN-UMIN000001014niversity of Tokyo6